IP Library Granted Patent US 11,155,801
Granted Patent B2
US 11,155,801 · App. 14/907,746 · Granted Oct 26, 2021

Unglycosylated lysostaphin variant protein

Inventors: Karl E. Griswold (Lyme, NH); Hongliang Zhao (Hanover, NH)
Assignee: Trustees of Dartmouth College
C12N9/52C12Y304/24075A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,155,801
App. No.
14/907,746
Granted
Oct 26, 2021
Kind
B2
Abstract

Unglycosylated lysostaphin variant protein, nucleic acid molecule, vector and host cell, as well as a method for production of unglycosylated lysostaphin variant protein in a yeast expression system are provided. The proteins are produced in a Pichia pastoris expression system and have been shown to have activity equivalent to wild-type lysostaphin. The lysostaphin variant proteins can be used as therapeutic proteins for treatment of diseases such as Staphylococcus aureus infection.

Claims (5)

1. A recombinant nucleic acid molecule encoding a lysostaphin protein or variant thereof, wherein the recombinant nucleic acid molecule encoding the lysostaphin protein or variant thereof comprises the nucleotide sequence of SEQ ID NO: 3, SEQ ID NO: 5 or SEQ ID NO: 7, and wherein the lysostaphin variant protein has endopeptidase activity.

2. The recombinant nucleic acid molecule of claim 1 , wherein the recombinant nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 5 and encodes a lysostaphin variant protein comprising the amino acid sequence of SEQ ID NO: 4.

3. The recombinant nucleic acid molecule of claim 2 , wherein the encoded lysostaphin variant protein is unglycosylated at the position corresponding to N125 of SEQ ID NO: 4, and wherein the lysostaphin variant protein has endopeptidase activity.

4. The recombinant nucleic acid molecule of claim 1 , wherein the recombinant nucleic acid molecule comprises the nucleotide sequence of SEQ ID NO: 7 and encodes a lysostaphin variant protein comprising the amino acid sequence of SEQ ID NO: 6.

5. The recombinant nucleic acid molecule of claim 4 , wherein the encoded lysostaphin variant protein is unglycosylated at the position corresponding to N125 of SEQ ID NO: 6, and wherein the lysostaphin variant protein has endopeptidase activity.

Assignments (4)
PATENT SECURITY AGREEMENT Recorded Oct 20, 2022
From: INSMED INCORPORATED
To: BIOPHARMA CREDIT PLC
Reel/Frame 061735/0875 →
SECOND LIEN PATENT SECURITY AGREEMENT Recorded Oct 19, 2022
From: INSMED INCORPORATED
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 061727/0039 →
CONFIRMATORY LICENSE Recorded Aug 6, 2018
From: DARMOUTH COLLEGE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046718/0608 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 27, 2016
From: GRISWOLD, KARL E.; ZHAO, HONGLIANG
To: TRUSTEES OF DARTMOUTH COLLEGE
Reel/Frame 037596/0070 →